Mepilex Border SacrumEconomic evidence
In a recent randomized controlled trial by Kalowes et al, Mepilex® Border Sacrum was associated with an 88% reduction in risk of of pressure ulcers. For an ICU department with 1,000 admissions, this pressure ulcer reduction could translate to significant cost savings.
The authors state:
"Cost savings for our health system have been significant ... Organizational estimates demonstrate that a savings of more than $1 million has been amortized in the past two years, after dressing purchase. This estimate is most likely conservative, given that the Society of Actuaries estimates the cost of treating a pressure ulcer ranges from $2,000 to $20,000 per ulcer, depending on severity. This cost savings estimate related to prevention is also consistent with other cost analysis studies of pressure ulcers."